Skip to main content
OpenTrials

Clinical trial condition

NSCLC

Explore clinical trials studying NSCLC. Study availability and eligibility vary by location and protocol.

357 public trials 121 recruiting studies
Refine in advanced search Browse all conditions

NSCLC trial results

Completed

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

NCT05668585

Conditions
ATC, CRC, Melanoma, +13 more
Locations
  • University of Arizona - Cancer Center Tucson, Arizona, United States
  • Florida Cancer Specialists Sarasota, Florida, United States
  • Community Health Network Indianapolis, Indiana, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 26 locations
View Trial Details
Completed

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NCT01221077

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • University of California, San Diego/Moores Cancer Center La Jolla, California, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Cleveland Clinic Florida Weston, Florida, United States
  • Northwestern Memorial Hospital Chicago, Illinois, United States
View all 29 locations
View Trial Details
Completed

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

NCT05383482

Conditions
Cervical Cancer, Digestive System Diseases, Digestive System Neoplasms, +24 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Chongqing Cancer Hospital Chongqing, Chengdu, China
  • Jilin Cancer Hospital Changchun, Jilin, China
  • Zhongshan Hospital, Fudan University Shanghai, Shanghai Municipality, China
View Trial Details
Completed

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

NCT05259696

Conditions
Adnexal Diseases, Bladder Cancer, Breast Cancer, +68 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of Southern California Los Angeles, California, United States
  • Stanford Health Care Stanford, California, United States
  • Yale University Cancer Center New Haven, Connecticut, United States
View all 13 locations
View Trial Details

Related conditions